This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Resumen de acción FSTX
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
Competidores de F-star Therapeutics, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.12 |
| 52 Week High | US$7.12 |
| 52 Week Low | US$2.07 |
| Beta | -0.35 |
| 1 Month Change | 47.72% |
| 3 Month Change | 26.47% |
| 1 Year Change | 138.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 75.37% |
Noticias y actualizaciones recientes
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15Recent updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Jul 29F-star enters license deal with Takeda for a cancer immune therapy antibody
Jul 20Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues
May 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results
Mar 17These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts
Mar 16F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
Jan 27F-star Therapeutics under pressure on pricing $65M stock offering
May 07Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like
Mar 17Merck KGaA discloses 5.4% stake in F-star Therapeutics
Feb 02Dosing underway in early-stage study of F-star's FS120 in cancer
Dec 03Rentabilidad de los accionistas
| FSTX | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 29.5% | 4.4% | 0.6% |
| 1Y | 138.1% | 2.8% | 23.9% |
Rentabilidad vs. Industria: FSTX exceeded the US Biotechs industry which returned 2.8% over the past year.
Rentabilidad vs. Mercado: FSTX exceeded the US Market which returned -9.9% over the past year.
Volatilidad de los precios
| FSTX volatility | |
|---|---|
| FSTX Average Weekly Movement | 27.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: FSTX's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: FSTX's weekly volatility has increased from 18% to 27% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2002 | 86 | Eliot Forster | www.f-star.com |
Resumen de fundamentos de F-star Therapeutics, Inc.
| Estadísticas fundamentales de FSTX | |
|---|---|
| Capitalización bursátil | US$156.51m |
| Beneficios(TTM) | -US$44.75m |
| Ingresos (TTM) | US$21.18m |
7.4x
Ratio precio-ventas (PS)-3.5x
Ratio precio-beneficio (PE)¿Está FSTX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de FSTX | |
|---|---|
| Ingresos | US$21.18m |
| Coste de los ingresos | US$0 |
| Beneficio bruto | US$21.18m |
| Otros gastos | US$65.92m |
| Beneficios | -US$44.75m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.04 |
| Margen bruto | 100.00% |
| Margen de beneficio neto | -211.32% |
| Ratio deuda/patrimonio | 17.3% |
¿Cómo se ha desempeñado FSTX a largo plazo?
Ver rendimiento histórico y comparativa